NCT06742996
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 35 versions: 35 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites reduced: 150 → 145 locations
- Study description expanded, about 278 words
- Notable Eligibility criteria expanded, about 15 words
- Trial sites reduced: 155 → 150 locations
- Secondary endpoints: details revised at 2 of 10 entries
- Minor Study sites revised (155)v33
- Minor Site details revised at 2 of 155 sitesv32
- Minor Site details revised at 28 of 155 sitesv31
- Minor Trial sites expanded: 152 → 155 locationsv30
- Minor Study sites revised (152)v29
- Minor Study sites: 151 to 152v28
- Minor Study sites: 149 to 151v27
- Minor Study sites: 148 to 149v26
- Minor Study sites: 149 to 148v25
- Minor Study sites revised (149)v24
- Minor Study sites revised (149)v23
- Minor Study sites: 148 to 149v22
- Minor Site details revised at 1 of 148 sitesv21
Notable Lead sponsor: BeiGene to BeOne Medicinesv20 Show 7 more changesShow less
- Eligibility criteria expanded, about 39 words
- Study sites: 141 to 148
- Primary completion date: Mar 31, 2029 to Aug 31, 2028
- Study completion date: Oct 30, 2032 to Mar 30, 2032
- Secondary endpoints: details revised at 9 of 10 entries
- Study description expanded, about 35 words
- Study title expanded, about 1 word
- Minor Study sites: 138 to 141v19
- Minor Study sites: 133 to 138v18
- Minor Study sites: 148 to 133v17
- Minor Study sites revised (148)v16
- Minor Site details revised at 6 of 148 sitesv15
- Minor Site details revised at 21 of 148 sitesv14
- Minor Site details revised at 8 of 148 sitesv13
- Minor Study sites revised (148)v12
- Minor Study sites revised (148)v11
- Minor Study sites revised (148)v10
- Minor Site details revised at 5 of 148 sitesv9
- Minor Study sites: 146 to 148
- Start date: Feb 25, 2025 to Mar 5, 2025
- Minor Study sites revised (146)v7
- Minor Study sites: 145 to 146v6
- Minor Study sites: 140 to 145v5
- Minor Study sites: 138 to 140v4
- Minor Study sites: 1 to 138v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of Jan 28, 2025 to Feb 25, 2025
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Progression-Free Survival (PFS) as assessed by Blinded Independent Review Committee (BIRC)
Timeframe: Approximately 41 months
Secondary (10)
Overall Survival (OS)
PFS as assessed by investigator (INV)
Overall Response Rate (ORR) as assessed by BIRC and by INV
Duration of Response (DOR) as assessed by BIRC and by INV
Complete Response Rate (CRR) as assessed by BIRC and by INV
Show 5 moreShow less
Time to first response as assessed by BIRC and by INV
Time to initiation of new anticancer therapy
Health-Related Quality of Life (HRQoL) as Assessed by the European Organisation of Research and Treatment of Cancer-Quality of Life Questionnaire Non-Hodgkin Lymphoma High Grade Module 29 (EORTC-QLQ-NHL-HG29)
Health-Related Quality of Life (HRQoL) as Assessed by the European Organisation of Research and Treatment of Cancer-Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)
Number of participants with treatment-emergent adverse events (TEAEs)
Arms and interventions
Arm A: sonrotoclax plus zanubrutinibExperimental
Sonrotoclax and zanubrutinib will be administered in combination.
Arm B: placebo plus zanubrutinibPlacebo comparator
Placebo and zanubrutinib will be administered in combination.
Drugs: Sonrotoclax, Zanubrutinib, Placebo
Sites
145 sites in 17 countries
United States 41, China 19, Japan 18, Brazil 10, Germany 7, United Kingdom 7, South Korea 6, Australia 5, Italy 5, New Zealand 5, Poland 5, Argentina 4, France 4, Spain 4, Turkey (Türkiye) 3, Austria 1, Puerto Rico 1